Advertisement
Document › Details
ERS Genomics Ltd.. (3/12/19). "Press Release: ERS Genomics Provides Comment on Issuance of University of California CRISPR/Cas9 Patent including Uses of CRISPR »in a Cell«". Dublin.
Region | United States (USA) | |
Organisation | ERS Genomics Ltd. | |
Organisation 2 | Regents of the University of California, The | |
Group | University of California (System) | |
Product | CRISPR gene editing technology | |
Product 2 | IP services | |
Person | Charpentier, Emmanuelle (Helmholtz 201412 Professor at HZI) | |
Person 2 | Rhodes, Eric (ERS Genomics 201606–202405 CEO before Horizon Discovery + Sigma-Aldrich + Sangamo Biosciences) | |
U.S. Patent No. 10,227,611 issued to Dr. Emmanuelle Charpentier, University of California, and University of Vienna
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a new patent to Dr. Emmanuelle Charpentier, together with The Regents of the University of California and University of Vienna (collectively, UC). U.S. Patent No. 10,227,611 specifically includes uses of single guide RNA formats of the CRISPR/Cas9 technology ‘in a cell’. In a cell specifically includes any cell type, including animal, plant and human cells. ERS Genomics is an exclusive licensee of certain rights in the UC patents from Dr. Charpentier.
Eric Rhodes, CEO of ERS Genomics, said: “We are pleased that the seminal contribution of Dr. Charpentier and her colleagues to CRISPR/Cas9 technology continues to be recognized by patent offices in the United States and around the world.”
UC already has two granted patents relating to CRISPR/Cas9 in the U.S., with a fourth expected to grant soon.
For additional information please visit www.ersgenomics.com.
Media contact:
Katie Odgaard
Zyme Communications
Tel: +44(0)7787 502 947
Email: katie.odgaard@zymecommunications.com
About ERS Genomics www.ersgenomics.com
ERS Genomics is a biotechnology company based in Dublin, Ireland. The company was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; companion animal and livestock health; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. For additional information please visit www.ersgenomics.com.
Record changed: 2023-06-05 |
Advertisement
More documents for ERS Genomics Ltd.
- [1] ERS Genomics Ltd.. (9/4/24). "Press Release: ERS Genomics and Medicines Discovery Catapult Sign CRISPR/Cas9 License Agreement". Dublin & Cheshire....
- [2] ERS Genomics Ltd.. (5/13/24). "Press Release: ERS Genomics Appoints John E Milad as Chief Executive Officer". Stockholm....
- [3] ERS Genomics Ltd.. (3/26/24). "Press Release: Key Charpentier/Doudna CRISPR Patent Upheld by China National Intellectual Property Administration". Dublin....
- [4] ERS Genomics Ltd.. (3/13/24). "Press Release: Ricoh and ERS Genomics Enter into CRISPR/Cas9 License Agreement". Tokyo & Dublin....
- [5] Empyrean Neuroscience, Inc.. (10/18/22). "Press Release: Empyrean Neuroscience Launches with $22M Series A and Genetic Engineering Platform to Advance Pipeline of Neuroactive Compounds Targeting CNS Disorders". New York, NY & Cambridge....
- [6] ERS Genomics Ltd.. (8/17/21). "Press Release: ERS Genomics and Cellular Engineering Technologies Enter CRISPR/Cas9 License Agreement". Dublin & Coralville, IA....
- [7] ERS Genomics Ltd.. (6/1/21). "Press Release: Japanese Patent Office Upholds Key Charpentier/Doudna CRISPR Patent and Allows Third". Dublin....
- [8] ERS Genomics Ltd.. (3/3/21). "Press Release: ERS Genomics Licenses CRISPR Gene Editing Technology to Otsuka Pharmaceutical". Dublin....
- [9] ERS Genomics Ltd.. (3/1/21). "Press Release: ERS Genomics Expands Team With Appointment of Jon Kratochvil as VP Business Development". Dublin....
- [10] ERS Genomics Ltd.. (2/16/21). "Press Release: ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement". Dublin & Barcelona....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top